PROFILI MOLECOLARI E TRATTAMENTO
Transcript of PROFILI MOLECOLARI E TRATTAMENTO
![Page 1: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/1.jpg)
PROFILI MOLECOLARI E
TRATTAMENTO Modena, 23 Novembre 2018
Dr Fabio Gelsomino
![Page 2: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/2.jpg)
Outline
• Current biomarkers
RAS
BRAF
MSI
• Emergent biomarkers
• Monitoring the clonal evolution of CRC
![Page 3: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/3.jpg)
Outline
• Current biomarkers
RAS
BRAF
MSI
• Emergent biomarkers
• Monitoring the clonal evolution of CRC
![Page 4: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/4.jpg)
![Page 5: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/5.jpg)
![Page 6: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/6.jpg)
Current Biomarkers: BRAF
Pietrantonio F et al, 2015
Rowland A et al, 2016
![Page 7: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/7.jpg)
Stintzing S et al, 2017
Current Biomarkers: BRAF
![Page 8: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/8.jpg)
Corcoran R.B et al, 2018
Current Biomarkers: BRAF
![Page 9: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/9.jpg)
Corcoran R.B et al, 2018
Current Biomarkers: BRAF
![Page 10: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/10.jpg)
Confirmed ORR 41%
Van Cutsem E et al, 2018
Current Biomarkers: BRAF
![Page 11: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/11.jpg)
Barras D et al, 2017
Current Biomarkers: BRAF
![Page 12: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/12.jpg)
Jones JC et al, 2017
• 2,2% of pts
• 22% of all BRAF mutations
• Compared to BRAF V600:
- Younger
- M > F
- Left-sided
- MSS
- > OS
- possible coexisting RAS mutations
Current Biomarkers: BRAF
![Page 13: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/13.jpg)
Funkhouser et al, 2012
15% all stages 4% in stage IV
Current Biomarkers: MSI
![Page 14: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/14.jpg)
Le DT et al, 2015
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Current Biomarkers: MSI
![Page 15: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/15.jpg)
A phase 2, Single-arm Study of Pembrolizumab in Pretreated patients to Address Significant Patient Unmet Needs
KEYNOTE-164-3rd line (refractory)
Current Biomarkers: MSI
![Page 16: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/16.jpg)
A phase 3 Study of Pembrolizumab Monotherapy vs Standard Chemotherapy in 1L
MSI CRC
KEYNOTE-177-1st line
Current Biomarkers: MSI
![Page 17: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/17.jpg)
Nivolumab +/- Ipilimumab (Checkmate 142)
Overman MJ et al, 2016; Overman MJ et al, 2017
Current Biomarkers: MSI
![Page 18: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/18.jpg)
Overman MJ et al, 2017
Current Biomarkers: MSI
![Page 19: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/19.jpg)
Overman JM et al, 2018
Current Biomarkers: MSI
![Page 20: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/20.jpg)
Current Biomarkers: MSI
![Page 21: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/21.jpg)
Current Biomarkers: MSI
![Page 22: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/22.jpg)
Bourdais R et al, 2017
POLE mut 0,5-2% of mCRC Somatic > germline Germline mut associated with multiple adenoma and CRC (PPAP) Younger, male, right-sided, BRAF mut (32%), earlier-stage and better prognosis in early-stage Mutations in exonuclease domain of POLE associated with high mutation rate, multiple tumoral neo-epitopes and T-Lymphocytes infiltration STRONG RATIONALE FOR IMMUNOTHERAPY
Polymerase proofreading domain mutations: new opportunities for immunotherapy in hypermutatad colorectal cancer beyond MMR deficiency
Current Biomarkers: MSI
![Page 23: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/23.jpg)
Outline
• Current biomarkers
RAS
BRAF
MSI
• Emergent biomarkers
• Monitoring the clonal evolution of CRC
![Page 24: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/24.jpg)
Lin Nu et al, 2007
Sartore-Bianchi A et al, 2018
3-5% in KRAS exon
2 WT stage IV CRC;
distal > proximal
Emergent Biomarkers: HER-2
![Page 25: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/25.jpg)
Antoniotti C et al, 2018
Emergent Biomarkers: HER-2
![Page 26: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/26.jpg)
Sartore-Bianchi A et al, 2016
Hurwitz W et al, 2017
Emergent Biomarkers: HER-2
![Page 27: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/27.jpg)
Liu X et al, 2010
1-2% of de novo
mCRC
Emergent Biomarkers: c-MET
![Page 28: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/28.jpg)
Raghav K et al, 2016
Emergent Biomarkers: c-MET
![Page 29: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/29.jpg)
Emergent Biomarkers: c-MET
Van Cutsem E et al, 2014
![Page 30: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/30.jpg)
Emergent Biomarkers: c-MET
Rimassa L et al, 2017
![Page 31: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/31.jpg)
Emergent Biomarkers: c-MET
Rimassa L et al, 2017
![Page 32: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/32.jpg)
2.5% of CRC
Kloosterman WP et al, 2017
Emergent Biomarkers: gene fusions
![Page 33: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/33.jpg)
Pietrantonio F et al, 2017
0.2-2.4% of CRC
Elderly
Right-sided
Node-spreading
RAS WT
MSI-H
Poor prognosis
Resistance to anti-EGFR
Emergent Biomarkers: gene fusions
![Page 34: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/34.jpg)
Rolfo C et al, 2015
Emergent Biomarkers: gene fusions
![Page 35: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/35.jpg)
Sartore-Bianchi A et al, 2016
Emergent Biomarkers: gene fusions
![Page 36: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/36.jpg)
Emergent Biomarkers: gene fusions
![Page 37: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/37.jpg)
Emergent Biomarkers: gene fusions
![Page 38: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/38.jpg)
Russo M et al, 2015
Emergent Biomarkers: gene fusions
![Page 39: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/39.jpg)
Fuse MJ et al, 2017
Emergent Biomarkers: gene fusions
![Page 40: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/40.jpg)
Pietrantonio F et al, 2018
0,2%
Older pts
Right-sided
MSI-H
RAS and BRAF WT
Emergent Biomarkers: gene fusions
![Page 41: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/41.jpg)
Le Rolle AF et al, 2015
Emergent Biomarkers: gene fusions
![Page 42: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/42.jpg)
![Page 43: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/43.jpg)
Cremolini C et al, 2017
![Page 44: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/44.jpg)
Cremolini C et al, 2017
![Page 45: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/45.jpg)
Cremolini C et al, 2017
![Page 46: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/46.jpg)
Outline
• Current biomarkers
RAS
BRAF
MSI
• Emergent biomarkers
• Monitoring the clonal evolution of CRC
![Page 47: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/47.jpg)
Normanno N et al, 2018
Monitoring the clonal evolution of CRC
![Page 48: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/48.jpg)
Monitoring the clonal evolution of CRC
Normanno N et al, 2015
![Page 49: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/49.jpg)
Normanno N et al, 2018
Monitoring the clonal evolution of CRC
![Page 50: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/50.jpg)
Monitoring the clonal evolution of CRC
Hahn S et al, 2015; Jones F et al, 2016
![Page 51: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/51.jpg)
![Page 52: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/52.jpg)
![Page 53: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/53.jpg)
• Only 50% of patients with RAS and BRAF WT CRC achieve a response to anti-
EGFR
• A panel uncommon genetic alterations may help to «negatively hyperselect»
patients who benefit from anti-EGFR (PRESSING panel)
• HER-2,c-MET, NTRK and RET are not only predictor of resistance to anti-
EGFR but druggable targets
• Liquid biopsy is the most intriguing tool to monitor the molecular evolution of
the disease, but deserves further validations
Conclusions
![Page 54: PROFILI MOLECOLARI E TRATTAMENTO](https://reader030.fdocuments.net/reader030/viewer/2022041214/62512c77bb55a9292669a0a3/html5/thumbnails/54.jpg)
Thanks!!!